Correction: Cancer Incidence following Expansion of HIV Treatment in Botswana

Dryden‐Peterson, Scott; Medhin, Heluf; Kebabonye-Pusoentsi, Malebogo; Seage, George R.; Suneja, Gita; Kayembe, Mukendi; Mmalane, Mompati; Rebbeck, Timothy R.; Rider, Jennifer R.; Essex, M.; Lockman, Shahin

doi:10.1371/journal.pone.0138742

Cited by 8 publications

(3 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2,3 In Botswana, an upper middle-income country from this region, cervical cancer is the most common gynecologic cancer and the leading cause of cancer death among women. 1,4,5 The high prevalence of HIV in Botswana is an additional factor contributing to the increasing burden of cervical cancer. As of 2016, 21.9% of adults between age 15 and 49 are living with HIV in Botswana.…”

Section: Introductionmentioning

confidence: 99%

“…6 Nearly two-thirds of cervical cancer cases in Botswana occur in patients who are HIV-positive. 4,7 Cervical cancer is an AIDS-defining condition, yet its association with HIV-related immunosuppression is not fully understood. HIV-related immunodeficiency is known to increase the risk for acquisition and persistence of genital human papillomavirus (HPV) infection and leads to higher rates of cervical cancer.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Association Between CD4 Count and Chemoradiation Therapy Outcomes Among Cervical Cancer Patients With HIV

Grover

Mehta

Wang

et al. 2020

JAIDS Journal of Acquired Immune Deficiency Syndromes

View full text Add to dashboard Cite

Background:In Botswana, nearly two-thirds of cervical cancer patients are HIV-positive. This study examined the relationship between CD4 count and chemoradiation therapy outcomes among cervical cancer patients with HIV.Setting: A prospective cohort study of 231 HIV-positive women with locally invasive cervical cancer was conducted in Gaborone, Botswana from January 2015 to February 2018. Methods: Primary outcome was survival, defined as time from scheduled end of chemoradiation therapy to death or last contact with patient. Nadir CD4 count was defined as lowest CD4 available before cancer diagnosis. Delta CD4 count was defined as improvement from nadir CD4 to CD4 at cancer diagnosis. Hazard ratio (HR) analyses were adjusted for presenting variables (age, baseline hemoglobin, cancer stage, and performance status) and treatment variables (chemotherapy cycles and radiation dose).Results: 231 patients were included in nadir CD4 analysis; 139 were included in delta CD4 analysis. Higher delta CD4 was significantly associated with reduced mortality after adjusting for presenting and treatment variables (CD4 100-249: HR 0.45, 95% CI 0.21-0.95; CD4 ≥ 250: HR

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Association Between CD4 Count and Chemoradiation Therapy Outcomes Among Cervical Cancer Patients With HIV

Grover

Mehta

Wang

et al. 2020

JAIDS Journal of Acquired Immune Deficiency Syndromes

View full text Add to dashboard Cite

show abstract

“…Botswana is an upper-middle-income country in SSA with a population of 2.2 million, and the third highest prevalence of HIV in the world, 17.6% among the general population [9–12]. Breast cancer is the second most common malignant disease (after cervical cancer) diagnosed among women in Botswana, with an age adjusted incidence rate of 17.5 per 100,000 women [13, 14]. There are few retrospective analyses of breast cancer clinical and molecular profiles in SSA [15–19], and of breast cancer and HIV presentation in the developed world and Africa [20–31], but no published studies to our knowledge have reported the characteristics of breast cancer and HIV in Botswana.…”

Section: Introductionmentioning

confidence: 99%

Report of clinico-pathological features of breast cancer in HIV-infected and uninfected women in Botswana

Bhatia

Narasimhamurthy

Martei

et al. 2019

Infect Agents Cancer

Self Cite

View full text Add to dashboard Cite

BackgroundTo characterize the clinico-pathological features including estrogen receptor (ER), progesterone receptor (PR) and Her-2/neu (HER2) expression in breast cancers in Botswana, and to compare them by HIV status.MethodsThis was a retrospective study using data from the National Health Laboratory and Diagnofirm Medical Laboratory in Gaborone from January 1, 2011 to December 31, 2015. Clinico-pathological details of patients were abstracted from electronic medical records.ResultsA total of 384 unique breast cancer reports met our inclusion criteria. Of the patients with known HIV status, 42.7% (50/117) were HIV-infected. Median age at the time of breast cancer diagnosis was 54 years (IQR 44–66 years). HIV-infected individuals were more likely to be diagnosed before age 50 years compared to HIV-uninfected individuals (68.2% vs 23.8%, p < 0.001). The majority of patients (68.6%, 35/51) presented with stage III at diagnosis. Stage IV disease was not presented because of the lack of data in pathology records surveyed, and additionally these patients may not present to clinic if the disease is advanced. Overall, 68.9% (151/219) of tumors were ER+ or PR+ and 16.0% (35/219) were HER2+. ER+ or PR+ or both, and HER2- was the most prevalent profile (62.6%, 132/211), followed by triple negative (ER−/PR−/HER2-, 21.3%, 45/211), ER+ or PR+ or both, and HER2+, (9.0%, 19/211) and ER−/PR−/HER2+ (7.1%, 15/211). There was no significant difference in receptor status noted between HIV-infected and HIV-uninfected individuals.ConclusionsMajority of breast cancer patients in Botswana present with advanced disease (stage III) at diagnosis and hormone receptor positive disease. HIV-infected breast cancer patients tended to present at a younger age compared to HIV-uninfected patients. HIV status does not appear to be associated with the distribution of receptor status in breast cancers in Botswana.

show abstract

HPV-FRAME: A consensus statement and quality framework for modelled evaluations of HPV-related cancer control

Canfell

Kim²,

Kulasingam

et al. 2019

Papillomavirus Research

View full text Add to dashboard Cite

Intense research activity in HPV modelling over this decade has prompted the development of additional guidelines to those for general modelling. A specific framework is required to address different policy questions and unique complexities of HPV modelling. HPV-FRAME is an initiative to develop a consensus statement and quality-based framework for epidemiologic and economic HPV models. Its development involved an established process. Reporting standards have been structured according to seven domains reflecting distinct policy questions in HPV and cancer prevention and categorised by relevance to a population or evaluation. Population-relevant domains are: 1) HPV vaccination in pre-adolescent and young adolescent individuals; 2) HPV vaccination in older individuals; 3) targeted vaccination in men who have sex with men; 4) considerations for individuals living with HIV and 5) considerations for low- and middle-income countries. Additional considerations applicable to specific evaluations are: 6) cervical screening or integrated cervical screening and HPV vaccination approaches and 7) alternative vaccine types and alternative dosing schedules. HPV-FRAME aims to promote the development of models in accordance with an explicit framework, to better enable target audiences to understand a model's strength and weaknesses in relation to a specific policy question and ultimately improve the model's contribution to informed decision-making.

show abstract

Correction: Cancer Incidence following Expansion of HIV Treatment in Botswana

Cited by 8 publications

References 1 publication

Association Between CD4 Count and Chemoradiation Therapy Outcomes Among Cervical Cancer Patients With HIV

Association Between CD4 Count and Chemoradiation Therapy Outcomes Among Cervical Cancer Patients With HIV

Report of clinico-pathological features of breast cancer in HIV-infected and uninfected women in Botswana

HPV-FRAME: A consensus statement and quality framework for modelled evaluations of HPV-related cancer control

Contact Info

Product

Resources

About